IM-1617

About Immunome

Immunome is a clinical-stage biotech focused on developing first-in-class and best-in-class targeted oncology therapies, with a core competency in antibody-drug conjugates (ADCs). Founded in 2023 via the merger of Immunome and Morphimmune under Dr. Clay Siegall's leadership, the company has rapidly built a multi-asset pipeline anchored by a late-stage gamma secretase inhibitor (varegacestat) and novel ADCs. Its strategy leverages deep ADC development expertise to systematically optimize novel agents, pursue strategic acquisitions, and address significant unmet needs in solid tumors.

Therapeutic Areas

Other Undisclosed Solid Tumor Target Drugs